NCT01935336

Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers

A Phase II Study of Ponatinib in Cohorts of Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 171 (actual)
• Sponsor: University of Colorado, Denver · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This phase II trial studies how well ponatinib hydrochloride works in treating patients with stage III-IV lung cancer. Ponatinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Detailed description

This study will look at the safety and effectiveness of the investigational drug ponatinib in lung cancer. The investigators hope that ponatinib will work against tumors that have certain biomarkers. Therefore, the study will pre-screen patients for these certain biomarkers before enrolling them into the main treatment study. Different doses of ponatinib may be tested in this study.

Conditions

• Adenocarcinoma of the Lung
• Extensive Stage Small Cell Lung Cancer
• Limited Stage Small Cell Lung Cancer
• Recurrent Non-small Cell Lung Cancer
• Recurrent Small Cell Lung Cancer
• Stage IIIA Non-small Cell Lung Cancer
• Stage IIIB Non-small Cell Lung Cancer
• Stage IV Non-small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Ponatinib	Ponatinib 45mg taken by mouth each day at the same time with or without food

Timeline

• Start date: 2013-09-24
• Primary completion: 2017-01-01
• Completion: 2017-11-01
• First posted: 2013-09-05
• Last updated: 2022-02-11
• Results posted: 2022-02-11

Locations

1 site across 1 country: United States